Novel vaccine administration technologies have the potential to improve
vaccine developers' commercial competitiveness and to increase vaccination
safety and convenience. This report assesses key strategies, technologies and
products for novel dermal and mucosal vaccine administration. It also provides
an overview of opportunities and challenges for the sector and a future
outlook.
Scope of this research
In-depth analysis of key dermal and mucosal vaccine administration
technologies
Thorough assessment of the potential for selected vaccine administration
technologies
Review of industry and academic stakeholder opinions involved in the
vaccine administration sector
In-depth discussion of key opportunities and risks for novel vaccine
administration technologies
Research and analysis highlights
Needle-free vaccine delivery into and through the skin is an important focus
of vaccine research, with key technologies including intradermal patches,
microneedles and needle-free liquid, solid and powder injectors. Recognizing
the skin as an important immunologic organ, researchers mainly hope for an
improved immune response using this approach.
The largest potential for success of mucosal vaccine delivery lies in oral and
intranasal administration, while pulmonary vaccination appears less promising
due concerns regarding safety and reliable dosing. Careful selection of
suitable indications for mucosal delivery routes will be key to success in
this challenging sector.
Antigen stability, safety and efficacy are the key hurdles for novel vaccine
administration technologies. In times of restricted healthcare budgets,
pricing and manufacturing costs of novel vaccine administration systems need
to be kept to a minimum. Only the careful selection of suitable indications
will offer a route to commercial success.
Key reasons to purchase this research
Review profiles of key marketed and development-stage, dermal and mucosal
vaccine administration technologies and assess their future potential
Gain insight into the current state of vaccine administration technologies
and their future opportunities and challenges
Benefit from opinions of key industry and academic stakeholders in the
vaccine administration field
Table of Contents
Table of Contents
EXECUTIVE SUMMARY
Strategic scoping and focus
Datamonitor insight into the vaccine administration market
Related reports
Upcoming related reports
BRIEF HISTORY OF THE DEVELOPMENT OF VACCINE ADMINISTRATION SYSTEMS
Overview of past developments in the vaccine administration sector
RATIONALE FOR THE DEVELOPMENT OF NOVEL VACCINE ADMINISTRATION SYSTEMS
Unmet needs regarding vaccine administration differ between the developed
and the developing world
Vaccine delivery through needle / syringe injection is associated with
considerable health risks
Alternative vaccine delivery technologies could provide better protection
through a combined mucosal / systemic immune response
Compliance could be improved through painless delivery alternatives
Alternative delivery technologies could reduce or eliminate the need for a
cold chain
Increased ease of use and speed of vaccine delivery is a key achievable
for biodefense indications and mass vaccination campaigns
From a marketing perspective, vaccine administration could become an
advantage in highly competitive segments of the vaccines market
CHALLENGES FOR NOVEL VACCINE ADMINISTRATION SYSTEMS
The regulatory pathway for novel delivery systems is complicated
The oligopoly structure of the vaccines market and the decreasing funding
for biotech companies as a result of the economic downturn represent further
challenges
The limited knowledge of the molecular mechanisms linked to vaccine
administration hampers the development of new technologies
Cost constraints could dent the commercial opportunity of novel vaccine
administration systems
Various new technologies are currently in development for vaccine
administration
DERMAL VACCINE ADMINISTRATION
Transdermal vaccine delivery
General considerations
Transdermal vaccine delivery systems
Transdermal patches
Key transdermal patch systems in development for vaccine administration
Datamonitor assessment
Microneedles
Key microneedle-based systems in development for vaccine administration
Datamonitor assessment
Needle-free solid, liquid or powder injection technologies
General considerations
Key needle-free injection systems in development for vaccine
administration
Datamonitor assessment
MUCOSAL VACCINE ADMINISTRATION
Oral vaccine delivery
General considerations
Oral vaccine delivery systems
Marketed and pipeline oral vaccines
Datamonitor assessment
Intranasal vaccine delivery
General considerations
Intranasal vaccine delivery systems
Marketed and pipeline intranasal vaccines
Datamonitor assessment
Pulmonary vaccine delivery
General considerations
Pulmonary vaccine delivery systems
Marketed and pipeline pulmonary vaccines
Datamonitor assessment
BIBLIOGRAPHY
Literature
APPENDIX
Contributing experts
Academic key opinion leaders
Industry key opinion leaders
Conferences
Report methodology
TABLES
Table: Summary of key vaccine administration technologies in development,
2009
Table: Key transdermal patch technologies in active development for
vaccines, 2009
Table: SWOT analysis - transdermal patch vaccine delivery systems
Table: Key microneedle technologies in active development for vaccines
Table: SWOT analysis - microneedle vaccine delivery systems
Table: Key needle-free injector technologies in active development for
vaccines
Table: SWOT analysis - needle-free injection vaccine delivery systems
Table: Key marketed oral vaccines, April 2009
Table: Key oral pipeline vaccines, April 2009
Table: SWOT analysis - oral vaccine delivery systems
Table: Key marketed and pipeline nasal vaccines, March 2009
Table: Comparison of different classes of pulmonary inhaler devices
Table: Key pipeline pulmonary vaccines, March 2009
Table: SWOT analysis - pulmonary vaccine delivery systems
FIGURES
Figure: Key events in the history of vaccine administration
Figure: Unmet needs in vaccine administration in the developed and
developing worlds
Figure: Drivers and resistors for vaccine administration technology
development
Figure: Overview of the development stage and expected market entry of key
physical vaccine delivery technologies, 2009- 2019
Figure: Transdermal vaccine delivery
Figure: Transdermal patch vaccine delivery
Figure: Microneedle vaccine delivery
Figure: Becton Dickinson - BD Soluvia
Figure: 3M Drug Delivery Systems - Solid Microstructured Transdermal
System
Figure: Nanopass - MicroPyramids
Figure: Zosano Pharma' s ZP patch technology
Figure: Needle-free injector vaccine delivery
Figure: Glide Pharma' s Glide SDI
Figure: PharmaJet' s liquid jet injector
Figure: Mucosa-associated lymphoid tissue and aggregates
Figure: Generation of immunity through mucosal vaccination
Figure: Advantages and drawbacks of mucosal vaccination
Figure: Annual sales of RotaTeq versus Rotarix, 2006- 08
Figure: FluMist - vaccine sales in the US, 2004- 08
Figure: FluMist - CDC and private sector costs/dose in the US, 2004- 08
Stakeholder Opinions: Vaccine administration technologies - Beyond needles published by Datamonitor in April 3, 2009. This report consists of 162 pages and the price starts from US $ 3800.
